If You Invested in Angiodynamics (ANGO)

AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company that designs, manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers. According to company disclosures, AngioDynamics focuses on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients in oncology and surgical settings.

The company reports that it has organized its product portfolio into two primary platforms: Med Tech and Med Device. Med Tech comprises high-growth technology platforms, including the Auryon Atherectomy laser for peripheral arterial disease, Mechanical Thrombectomy products such as AngioVac and AlphaVac, and the NanoKnife irreversible electroporation (IRE) system for solid tumor ablation. Med Device comprises angiographic catheters, endovenous laser therapy (EVLT) products, port products, and other oncology products, as described in the company’s proxy materials.

Business focus and technology platforms

AngioDynamics states that its technologies and devices are chosen by physicians in fast‑growing healthcare markets to address unmet patient needs. In its filings and news releases, the company highlights three major areas of focus:

• Vascular interventions: Products aimed at restoring blood flow in the vascular system, including the Auryon Atherectomy System and Mechanical Thrombectomy platforms (AngioVac and AlphaVac).
• Cancer care: Technologies that expand treatment options for solid tumors, notably the NanoKnife System, which uses irreversible electroporation for soft tissue ablation, including prostate tissue.
• Supportive oncology and surgical devices: Angiographic catheters, ports, EVLT products, and other devices used in oncology and surgical settings, grouped under the Med Device platform.

The company reports that its Med Tech platform is a key growth driver, with Med Tech net sales including contributions from the Auryon peripheral atherectomy platform, the thrombus management platform, and the NanoKnife IRE platform.

Key products and clinical evidence

AngioDynamics’ public communications describe several named technologies:

• NanoKnife System: A non‑thermal, radiation‑free ablation system that uses irreversible electroporation (IRE) to destroy targeted soft tissue. The company reports that the NanoKnife System received U.S. FDA 510(k) clearance for prostate tissue ablation and is indicated in the United States for surgical ablation of soft tissue, including prostate tissue. In the European Union, it is indicated for ablation of prostate tissue in patients with intermediate‑risk prostate cancer.
• Auryon Atherectomy System: A laser atherectomy system for the treatment of infrainguinal peripheral arterial disease. Company materials state that it uses solid‑state laser technology at a 355 nm wavelength and is FDA‑cleared for treatment, including atherectomy, of infrainguinal stenoses and occlusions, including in‑stent restenosis.
• Mechanical Thrombectomy platform: This includes the AngioVac and AlphaVac systems. AngioDynamics reports FDA 510(k) clearance for a modified AlphaVac F1885 System with expanded indications, and FDA Investigational Device Exemption (IDE) approvals for studies such as the APEX‑Return study (AlphaReturn Blood Management System with AlphaVac F1885 for acute pulmonary embolism) and the PAVE clinical study (AngioVac System for right‑sided infective endocarditis).

The company highlights clinical research as an important part of its strategy. It reports that the PRESERVE study of the NanoKnife System for prostate tissue ablation in intermediate‑risk prostate cancer was published in European Urology, meeting its primary effectiveness endpoint and demonstrating preservation of urinary continence and sexual function at 12 months. AngioDynamics also notes enrollment of patients in trials such as AMBITION BTK (Auryon Atherectomy System in below‑the‑knee lesions for critical limb ischemia) and RECOVER‑AV (AlphaVac F1885 System for intermediate‑risk pulmonary embolism).

Med Tech and Med Device segments

In its proxy statement and earnings releases, AngioDynamics explains that it has undergone a strategic transformation toward a growth‑oriented, technology‑driven profile by organizing its portfolio into Med Tech and Med Device:

• Med Tech: High‑growth technology platforms, including the Auryon Atherectomy laser for peripheral arterial disease, Mechanical Thrombectomy products (AngioVac and AlphaVac), and NanoKnife IRE products for solid tumor ablation.
• Med Device: Angiographic catheters, EVLT products, port products, and other oncology products.

The company’s recent financial communications emphasize that Med Tech growth has been a major contributor to overall performance, and that product mix shifts toward Med Tech have supported improvements in gross margin.

Regulatory and recognition milestones

AngioDynamics’ news releases describe several regulatory and recognition milestones for its technologies:

• FDA 510(k) clearance for a modified AlphaVac F1885 System with expanded indications, including aspiration and injection of contrast media and other fluids, and an indication for the sheath used to insert endovascular devices.
• FDA IDE approvals for the APEX‑Return study (AlphaReturn Blood Management System with AlphaVac F1885 for acute pulmonary embolism) and the PAVE study (AngioVac System for right‑sided infective endocarditis).
• FDA Breakthrough Device designation for the AngioVac System for removal of right heart vegetation in right‑sided infective endocarditis.
• TIME’s recognition of the NanoKnife System on its 2025 Best Inventions list in the medical devices category, citing its use of IRE technology for prostate tumors and its potential to preserve urinary and sexual function compared with some traditional treatments.

Corporate and regulatory profile

AngioDynamics is incorporated in the United States and lists its common stock on the NASDAQ Global Select Market under the ticker symbol ANGO, as noted in its SEC filings. The company’s SEC reports describe it as a medical technology company in the surgical and medical instrument manufacturing space. AngioDynamics files periodic reports, proxy statements, and current reports with the U.S. Securities and Exchange Commission, and its shareholders vote on matters such as director elections, auditor ratification, and advisory approval of executive compensation.

In its proxy materials, AngioDynamics notes that it has organized its portfolio and strategic priorities to focus on larger and faster‑growing markets through its Med Tech and Med Device platforms. The company’s public communications emphasize clinical evidence, regulatory clearances, and product development as central elements of its approach to serving physicians and patients.

Investor considerations

Investors researching ANGO stock can find from company disclosures that AngioDynamics:

• Operates in medical technology, with a focus on vascular interventions and oncology.
• Reports results and outlook by Med Tech and Med Device platforms.
• Highlights clinical trials and peer‑reviewed publications supporting its technologies, including NanoKnife, Auryon, AngioVac, and AlphaVac.
• Provides guidance and uses non‑GAAP measures such as adjusted EBITDA and pro forma results in its earnings communications, with reconciliations to GAAP included in its releases.

According to its filings and news releases, AngioDynamics also communicates regularly with investors through earnings calls, conference presentations, and webcasts accessible via the investors section of its website.